Key result
Cardiac actin R312C/H variants reduce tropomyosin elongation rate by ~74% compared to wild-type.
Why the study?
Actin variants R312C and R312H displayed both hyperactivity and hypoactivity in vitro, contradicting traditional characterizations of HCM- and DCM-causing variants and prompting further study of differentiating mechanisms.
Do cardiac actin R312C and R312H amino acid substitutions alter actomyosin activity, regulatory protein interactions, and actin filament structure compared to wild-type actin in vitro and in silico?
Do cardiac actin R312C and R312H amino acid substitutions alter actomyosin activity, regulatory protein interactions, and actin filament structure compared to wild-type actin in vitro and in silico?
This study demonstrates that R312C and R312H cardiac actin variants cause both hyperactive and hypoactive sarcomeric traits through a gradient of altered regulatory protein interactions and opposing structural shifts in actin's D-loop, challenging the simplistic paradigm that HCM and DCM are strictly defined by uniform sarcomere hyperactivity and hypoactivity.
Answers are grounded in this paper and cite their sources.
May inform mixed sarcomeric phenotypes in cardiomyopathy; challenges binary hyperactivity/hypoactivity models for HCM versus DCM.
Two common types of cardiovascular disease are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) which occur from changes to sarcomere contractile mechanisms and activity. Actin amino acid substitutions R312C and R312H have been found in HCM and DCM patients, respectively. Previously, we observed that R312C/H variants display both hyperactivity and hypoactivity in vitro, contradicting traditional characterizations of HCM- and DCM-causing variants. Here, we further characterized R312C/H actin variants in vitro and conducted in silico modeling to better understand the mechanisms differentiating HCM and DCM. Our results suggest that R312C/H substitutions cause structural changes that differentially impact actomyosin activity. A gradient of altered interactions with regulatory proteins troponin, tropomyosin, and the C0C2 domains of myosin-binding protein C was also observed, influencing the accessibility of active and inhibitory conformations of these proteins. The results presented here support our previous suggestion of a gradient of factors that differentiate between HCM and DCM. Further characterization of HCM- and DCM-causing actin variants using in vitro and in silico methods is required for better understanding cardiomyopathy and improving clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Steffensen et al. (2024) studied Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Cardiac actin (ACTC) R312C and R312H amino acid substitutions vs. Wild-type recombinant cardiac actin (WTRec / WT) was evaluated on Tropomyosin kinetic binding elongation rate (/s) (p=0.0004). Actin R312C/H variants reduced tropomyosin elongation rate and impaired tropomyosin inhibition of filament velocity.
Synapse has enriched 10 related papers. Consider them for comparative context: